FRIDAY, Nov. 22, 2019 -- Restrictive Medicaid policies are associated with a reduced proportion of payment by Medicaid for liver transplantation (LT) for alcohol-related liver disease (ALD) since 2011, according to a study published online Nov. 8 in Hepat
FDA Approves Givlaari
FDA Approves Givlaari (givosiran) for Acute Hepatic Porphyria
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 20, 2019 --Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S
FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
21 November 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia
Treatment Response Rates High for Seniors With Hep C Infection
FRIDAY, Nov. 15, 2019 -- For patients with chronic hepatitis C infection, sustained viral response (SVR) rates are similar for those aged 65 years and older and those younger than 65, accordi
FDA Approves Fetroja
FDA Approves Fetroja (cefiderocol) for the Treatment of Complicated Urinary Tract Infections
November 14, 2019 -- The U.S. Food and Drug Administration today approved Fetroja (cefiderocol), an antibacterial drug for treatment of p
FDA Approves Brukinsa
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
CAMBRIDGE, Mass. and BEIJING, China, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical